Beta Bionics (NASDAQ:BBNX) Shares Up 8.7% – Here’s Why

Shares of Beta Bionics, Inc. (NASDAQ:BBNX) traded up 8.7% during mid-day trading on Wednesday . The stock traded as high as $14.77 and last traded at $14.8650. 91,405 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 1,128,585 shares. The stock had previously closed at $13.67.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Bank of America decreased their price target on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research note on Monday, May 18th. Weiss Ratings downgraded Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Stifel Nicolaus decreased their target price on Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. The Goldman Sachs Group dropped their price target on shares of Beta Bionics from $19.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Finally, Leerink Partners reduced their price target on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a research note on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Beta Bionics presently has a consensus rating of “Moderate Buy” and an average target price of $19.70.

Beta Bionics Stock Performance

The company has a market cap of $708.95 million, a P/E ratio of -10.54 and a beta of 3.40. The firm’s fifty day moving average is $12.05 and its two-hundred day moving average is $15.57.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings results on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. The business had revenue of $27.63 million for the quarter. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%. On average, equities research analysts expect that Beta Bionics, Inc. will post -2.22 EPS for the current year.

Insider Buying and Selling at Beta Bionics

In other Beta Bionics news, Director Christy Jones sold 2,811 shares of Beta Bionics stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $14.00, for a total value of $39,354.00. Following the sale, the director directly owned 27,400 shares in the company, valued at approximately $383,600. The trade was a 9.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen Feider sold 6,676 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total transaction of $84,184.36. Following the completion of the sale, the chief financial officer owned 166,053 shares in the company, valued at approximately $2,093,928.33. The trade was a 3.87% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 30,351 shares of company stock worth $383,559. Insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Beta Bionics

Hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its holdings in Beta Bionics by 0.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company’s stock valued at $10,105,000 after buying an additional 931 shares in the last quarter. Deutsche Bank AG grew its holdings in shares of Beta Bionics by 3.4% in the fourth quarter. Deutsche Bank AG now owns 39,300 shares of the company’s stock valued at $1,197,000 after purchasing an additional 1,296 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in Beta Bionics by 203.6% in the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after purchasing an additional 1,594 shares during the last quarter. Summit Securities Group LLC purchased a new stake in Beta Bionics during the fourth quarter valued at $52,000. Finally, Caitong International Asset Management Co. Ltd grew its stake in shares of Beta Bionics by 1,075.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after buying an additional 1,818 shares in the last quarter.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.